New drug SRG-514 tested during breast cancer surgery
Disease control
Ongoing
This early-phase trial tests a new drug called SRG-514, which is applied directly to the tumor site during breast-conserving surgery. The goal is to find the safest dose and see how the body handles it. About 24 adults with breast cancer are taking part. This study focuses on saf…
Phase: PHASE1 • Sponsor: SURGE Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:56 UTC